Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis

Documents similaires

• Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
  par: Alex E. Henney, et autres
  Publié: (2024)
• Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease
  par: Weronika Stupalkowska, et autres
  Publié: (2025)
• Real‐world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement
  par: Sahana Mahesh, et autres
  Publié: (2025)
• The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real‐world retrospective cohort study
  par: Sophie Haughton, et autres
  Publié: (2025)
• Hydrogel dressings for diabetic foot ulcer: A systematic review and meta‐analysis
  par: Hongjiao Zhao, et autres
  Publié: (2024)